Inhibikase Therapeutics Inc — Cash Flow (NASDAQ:IKT) | MetaTrader

Open full chart

Financials

Overview Отчетность Statistics Dividends

Quarterly Annual

Cash from operating activities -14.3 M-17.35 M-18.09 M-19.15 M -25.62 M Cash from investing activities —-16.01 M11.66 M-37 M -36.61 M Cash from financing activities 41.09 M-204.77 K8.41 M103.48 M 99.58 M Free cash flow -14.3 M-17.59 M-18.1 M-19.15 M -25.63 M

Новости

BofA Securities начинает покрытие акций Inhibikase с рейтингом "Покупать"

BofA Securities initiates coverage on Inhibikase stock with Buy rating

Jefferies сохраняет рейтинг "Покупать" для акций Inhibikase

Jefferies reiterates Buy rating on Inhibikase stock, citing faster FDA path

H.C. Wainwright начинает покрытие акций Inhibikase с рейтингом "Покупать"

H.C. Wainwright assumes coverage on Inhibikase stock with Buy rating

Monday’s Insider Activity: Top Executives Trade Shares at Tech Giants

Why Intuit Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket - Gap (NYSE:GAP), Elastic (NYSE:ESTC)

Inhibikase Therapeutics оценивает публичное размещение в $100 млн

Inhibikase Therapeutics prices $100 million public offering

Акции Inhibikase Therapeutics падают после объявления о размещении

Inhibikase Therapeutics stock falls after announcing public offering